Blinded and seeing the light, (John Noseworthy, Lou Gehrig and other tales of enlightenment)

Seminars in Neurology

Volumn 18, Issue 3, 1998, Pages 415-418

  Pascuzzi, Robert M ^a  

^a NONE

Author keywords

Amyotrophic lateral sclerosis; Clinical trials; Double blinding; Lou Gehrig; Multiple sclerosis; Noseworthy

Indexed keywords

ALPHA TOCOPHEROL; PREDNISONE;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL RESEARCH; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; PATIENT CARE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0031796529     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1040891     Document Type: Short Survey

References (7)

1. Noseworthy JH, Ebers GC, Vandervoort MK, Farquhar RE, Yetisir E, Roberts R The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 1944;44:16-20
2. Goshorn R. Chronic fatigue syndrome: A review for clinicians. Seminars in Neurology 1998;18(2):237-242
3. Berg AO. Placebos: A brief review for family physicians. Journal of Family Practice 1977;5.97-100
4. Beecher HK. The powerful placebo. JAMA 1955;159:1602-1606
5. Wechsler IS The treatment of amyotrophic lateral sclerosis with Vitamin E (tocopherols). The American Journal of the Medical Sciences. 1940;200:765-778
6. Kean JR. "Historical intelligence" amyotrophic lateral sclerosis and vitamin E. The Annals of Neurology 1966;40:480
7. Reider CR, Paulson GW. Lou Gehrig and amyotrophic lateral sclerosis: Is vitamin E to be revisited? Archives of Neurology 1997;54:527-528